Physician profile
Marcel Pintea
NPI 1871549550
$499.32
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $210.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $215.59 | 2019-2020 | |
| Abbott Laboratories | $96.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.34 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.34 | 2020 | |
| Lilly USA, LLC | $14.46 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcel Pintea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.